{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:13:06Z","timestamp":1793419986062,"version":"4.5.0"},"reference-count":68,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,28]]},"abstract":"<jats:p>Park et al describe a novel KLF4-mediated pathway that promotes chromic myeloid leukemia (CML) stem cell (LSC) survival. Deletion of KLF4 in a mouse model of CML decreases LSC survival through repression of Dyrk2, resulting in c-Myc depletion and increased p53 activity.<\/jats:p>","DOI":"10.1182\/blood.2018875922","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T04:45:12Z","timestamp":1568349912000},"page":"1960-1972","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["A KLF4-DYRK2\u2013mediated pathway regulating self-renewal in CML stem cells"],"prefix":"10.1182","volume":"134","author":[{"given":"Chun Shik","family":"Park","sequence":"first","affiliation":[{"name":"Department of Pathology and Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology and"},{"name":"Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor J.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology and"},{"name":"Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5200-2513","authenticated-orcid":false,"given":"Cory S.","family":"Bridges","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology and"},{"name":"Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koramit","family":"Suppipat","sequence":"additional","affiliation":[{"name":"Texas Children\u2019s Cancer and Hematology Center, Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Puppi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Tomolonis","sequence":"additional","affiliation":[{"name":"MD\/PhD Program, Baylor College of Medicine, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Pang","sequence":"additional","affiliation":[{"name":"Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni-Ann","family":"Mistretta","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyuan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4096-6603","authenticated-orcid":false,"given":"Rachel","family":"Rau","sequence":"additional","affiliation":[{"name":"Department of Pediatrics-Oncology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0660-617X","authenticated-orcid":false,"given":"H. Daniel","family":"Lacorazza","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019112811585486900_B1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/138920111794295747","article-title":"Cancer stem cells in hematological disorders: current and possible new therapeutic approaches","volume":"12","author":"Annaloro","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"2019112811585486900_B2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/156800911793743655","article-title":"Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept","volume":"11","author":"Valent","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"issue":"31","key":"2019112811585486900_B3","doi-asserted-by":"crossref","first-page":"31ps21","DOI":"10.1126\/scitranslmed.3000914","article-title":"Targeting myeloid leukemia stem cells","volume":"2","author":"Jordan","year":"2010","journal-title":"Sci Transl Med"},{"issue":"2","key":"2019112811585486900_B4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11899-012-0121-6","article-title":"Chronic myeloid leukemia stem cell biology","volume":"7","author":"Crews","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"2019112811585486900_B5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4161\/cc.7.5.5549","article-title":"Leukemia and hematopoietic stem cells: balancing proliferation and quiescence","volume":"7","author":"Jude","year":"2008","journal-title":"Cell Cycle"},{"issue":"2","key":"2019112811585486900_B6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrg2269","article-title":"Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation","volume":"9","author":"Orford","year":"2008","journal-title":"Nat Rev Genet"},{"issue":"2","key":"2019112811585486900_B7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11899-012-0117-2","article-title":"Curing chronic myeloid leukemia","volume":"7","author":"Rea","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"2019112811585486900_B8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc2368","article-title":"Getting to the stem of chronic myeloid leukaemia","volume":"8","author":"Savona","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2019112811585486900_B9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bcp.2010.05.001","article-title":"Targeted therapy of chronic myeloid leukemia","volume":"80","author":"Sullivan","year":"2010","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"2019112811585486900_B10","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2004-08-3373","article-title":"Punish the parent not the progeny","volume":"105","author":"Elrick","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2019112811585486900_B11","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019112811585486900_B12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019112811585486900_B13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019112811585486900_B14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019112811585486900_B15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","article-title":"Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia","volume":"29","author":"Cortes","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019112811585486900_B16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/14712598.2014.867323","article-title":"Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia","volume":"14","author":"Morotti","year":"2014","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"2019112811585486900_B17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019112811585486900_B18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2012.08.006","article-title":"Selective elimination of leukemia stem cells: hitting a moving target","volume":"338","author":"Crews","year":"2013","journal-title":"Cancer Lett"},{"issue":"11","key":"2019112811585486900_B19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/ncb1314","article-title":"The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene","volume":"7","author":"Rowland","year":"2005","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2019112811585486900_B20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/carcin\/bgi243","article-title":"Emerging role of KLF4 in human gastrointestinal cancer","volume":"27","author":"Wei","year":"2006","journal-title":"Carcinogenesis"},{"issue":"2","key":"2019112811585486900_B21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.onc.1207067","article-title":"Identification of Kr\u00fcppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer","volume":"23","author":"Zhao","year":"2004","journal-title":"Oncogene"},{"issue":"3","key":"2019112811585486900_B22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ncb1698","article-title":"A core Klf circuitry regulates self-renewal of embryonic stem cells","volume":"10","author":"Jiang","year":"2008","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2019112811585486900_B23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nbt1374","article-title":"Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts","volume":"26","author":"Nakagawa","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2019112811585486900_B24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"issue":"4","key":"2019112811585486900_B25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"issue":"9","key":"2019112811585486900_B26","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-12-256446","article-title":"KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma","volume":"116","author":"Guan","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019112811585486900_B27","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3324\/haematol.2012.066944","article-title":"Kr\u00fcppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma","volume":"98","author":"Schoenhals","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"2019112811585486900_B28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10238-012-0187-4","article-title":"KLF4 translation level is associated with differentiation stage of different pediatric leukemias in both cell lines and primary samples","volume":"13","author":"Guo","year":"2013","journal-title":"Clin Exp Med"},{"issue":"1","key":"2019112811585486900_B29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1172\/JCI64745","article-title":"CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPAR\u03b3 signaling","volume":"123","author":"Faber","year":"2013","journal-title":"J Clin Invest"},{"issue":"6","key":"2019112811585486900_B30","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/leu.2016.339","article-title":"Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway","volume":"31","author":"Shen","year":"2017","journal-title":"Leukemia"},{"issue":"18","key":"2019112811585486900_B31","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.4161\/cc.21404","article-title":"Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control","volume":"11","author":"Becker","year":"2012","journal-title":"Cell Cycle"},{"issue":"11","key":"2019112811585486900_B32","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bcp.2008.05.021","article-title":"Role for DYRK family kinases on regulation of apoptosis","volume":"76","author":"Yoshida","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"2019112811585486900_B33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ncb3306","article-title":"Ramping up degradation for proliferation","volume":"18","author":"Huibregtse","year":"2016","journal-title":"Nat Cell Biol"},{"issue":"6","key":"2019112811585486900_B34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/15384101.2015.1007751","article-title":"Engagement of DYRK2 in proper control for cell division","volume":"14","author":"Nihira","year":"2015","journal-title":"Cell Cycle"},{"issue":"3","key":"2019112811585486900_B35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1172\/JCI60818","article-title":"DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells","volume":"122","author":"Taira","year":"2012","journal-title":"J Clin Invest"},{"issue":"5","key":"2019112811585486900_B36","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.molcel.2007.02.007","article-title":"DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage","volume":"25","author":"Taira","year":"2007","journal-title":"Mol Cell"},{"key":"2019112811585486900_B37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-1-4939-7371-2_13","article-title":"Retroviral transduction of quiescent murine hematopoietic stem cells","volume":"1686","author":"Park","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"4","key":"2019112811585486900_B38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/gene.10161","article-title":"VavCre transgenic mice: a tool for mutagenesis in hematopoietic and endothelial lineages","volume":"34","author":"Georgiades","year":"2002","journal-title":"Genesis"},{"issue":"7","key":"2019112811585486900_B39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2005.05.026","article-title":"SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells","volume":"121","author":"Kiel","year":"2005","journal-title":"Cell"},{"issue":"8","key":"2019112811585486900_B40","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1073\/pnas.1100764108","article-title":"Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression","volume":"109","author":"Zhang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019112811585486900_B41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"issue":"7607","key":"2019112811585486900_B42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"issue":"7","key":"2019112811585486900_B43","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.cell.2013.05.041","article-title":"The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability","volume":"153","author":"King","year":"2013","journal-title":"Cell"},{"issue":"2","key":"2019112811585486900_B44","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/eji.200737972","article-title":"Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse","volume":"38","author":"Huang","year":"2008","journal-title":"Eur J Immunol"},{"issue":"5","key":"2019112811585486900_B45","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jmcb\/mjs047","article-title":"Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways","volume":"4","author":"P\u00e9rez","year":"2012","journal-title":"J Mol Cell Biol"},{"issue":"6","key":"2019112811585486900_B46","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1755-148X.2009.00628.x","article-title":"Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis","volume":"22","author":"Shah","year":"2009","journal-title":"Pigment Cell Melanoma Res"},{"key":"2019112811585486900_B47","doi-asserted-by":"crossref","first-page":"727","DOI":"10.12659\/MSM.908553","article-title":"Inhibition of Siah2 ubiquitin ligase by vitamin K3 attenuates chronic myeloid leukemia chemo-resistance in hypoxic microenvironment","volume":"24","author":"Huang","year":"2018","journal-title":"Med Sci Monit"},{"issue":"7","key":"2019112811585486900_B48","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2004.06.001","article-title":"Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia","volume":"117","author":"Nakayama","year":"2004","journal-title":"Cell"},{"issue":"1","key":"2019112811585486900_B49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-015-0407-0","article-title":"BCR\/ABL1 and BCR are under the transcriptional control of the MYC oncogene","volume":"14","author":"Sharma","year":"2015","journal-title":"Mol Cancer"},{"key":"2019112811585486900_B50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-4939-4011-0_13","article-title":"A convenient cell culture model for CML acquired resistance through BCR-ABL mutations","volume":"1465","author":"Wang","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"6","key":"2019112811585486900_B51","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"issue":"2","key":"2019112811585486900_B52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.stem.2012.05.021","article-title":"Targeting tetramer-forming GABP\u03b2 isoforms impairs self-renewal of hematopoietic and leukemic stem cells","volume":"11","author":"Yu","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"21","key":"2019112811585486900_B53","doi-asserted-by":"crossref","first-page":"11148","DOI":"10.1074\/jbc.M116.717801","article-title":"Hematopoietic and leukemic stem cells have distinct dependence on Tcf1 and Lef1 transcription factors","volume":"291","author":"Yu","year":"2016","journal-title":"J Biol Chem"},{"issue":"2","key":"2019112811585486900_B54","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.stem.2016.05.004","article-title":"ADAR1 activation drives leukemia stem cell self-renewal by impairing Let-7 biogenesis","volume":"19","author":"Zipeto","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"3","key":"2019112811585486900_B55","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.stem.2017.08.001","article-title":"Prostaglandin E1 and its analog misoprostol inhibit human CML stem cell self-renewal via EP4 receptor activation and repression of AP-1","volume":"21","author":"Li","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"13","key":"2019112811585486900_B56","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/onc.2016.349","article-title":"Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer","volume":"36","author":"Mimoto","year":"2017","journal-title":"Oncogene"},{"issue":"2","key":"2019112811585486900_B57","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ncb3289","article-title":"Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis","volume":"18","author":"Guo","year":"2016","journal-title":"Nat Cell Biol"},{"key":"2019112811585486900_B58","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijbiomac.2015.08.067","article-title":"Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in non-Hodgkin\u2019s lymphoma","volume":"81","author":"Wang","year":"2015","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"2019112811585486900_B59","doi-asserted-by":"crossref","first-page":"e0159954","DOI":"10.1371\/journal.pone.0159954","article-title":"Low expression of DYRK2 (dual specificity tyrosine phosphorylation regulated kinase 2) correlates with poor prognosis in colorectal cancer","volume":"11","author":"Yan","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"2019112811585486900_B60","doi-asserted-by":"crossref","first-page":"11021","DOI":"10.1007\/s13277-014-2413-z","article-title":"Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer","volume":"35","author":"Enomoto","year":"2014","journal-title":"Tumour Biol"},{"issue":"3","key":"2019112811585486900_B61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ccr.2013.01.025","article-title":"Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression","volume":"23","author":"Reavie","year":"2013","journal-title":"Cancer Cell"},{"issue":"7569","key":"2019112811585486900_B62","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"issue":"2","key":"2019112811585486900_B63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF01202221","article-title":"Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial","volume":"121","author":"Tetef","year":"1995","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"2019112811585486900_B64","first-page":"817","article-title":"Vitamin K1 versus vitamin K3 for prevention of subclinical vitamin deficiency: a randomized controlled trial","volume":"44","author":"Chawla","year":"2007","journal-title":"Indian Pediatr"},{"issue":"9","key":"2019112811585486900_B65","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1440-1746.2006.04383.x","article-title":"High dose vitamin K3 infusion in advanced hepatocellular carcinoma","volume":"21","author":"Sarin","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"2019112811585486900_B66","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10637-005-6731-2","article-title":"Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy","volume":"23","author":"Lim","year":"2005","journal-title":"Invest New Drugs"},{"issue":"8","key":"2019112811585486900_B67","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2174\/1871520616666160310143316","article-title":"Anticancer vitamin K3 analogs: a review","volume":"16","author":"Badave","year":"2016","journal-title":"Anticancer Agents Med Chem"},{"issue":"15","key":"2019112811585486900_B68","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2174\/092986709788186057","article-title":"In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells","volume":"16","author":"Verrax","year":"2009","journal-title":"Curr Med Chem"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/22\/1960\/1543152\/blood875922.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/22\/1960\/1543152\/blood875922.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T10:29:02Z","timestamp":1721730542000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/22\/1960\/374983\/A-KLF4DYRK2mediated-pathway-regulating-selfrenewal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":68,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,11,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2018875922","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]}}}